Inhibrx Biosciences, Inc. 8-K

What Happened

• Inhibrx Biosciences, Inc. filed a Form 8-K on February 23, 2026 (Item 7.01) to disclose under Regulation FD that it posted an updated corporate presentation to the "Investors" section of its website (www.inhibrx.com). The presentation is attached to the filing as Exhibit 99.1. The company stated it may present or distribute this deck at conferences and investor meetings and that it has no obligation to update or amend the attached materials.

Key Details

• Filing date: February 23, 2026 (Regulation FD disclosure, Item 7.01).
• Updated corporate presentation posted to the company website and attached as Exhibit 99.1 to the 8-K.
• Company expressly disclaims any obligation to update, supplement, or amend the presentation.
• Report signed by CFO Kelly Deck on behalf of Inhibrx (Item 9.01 exhibits referenced).

Why It Matters

• This is a disclosure of new investor-facing materials, not an earnings release or new financial results. Retail investors should view the presentation as an informational update the company is using to communicate strategy, programs, or progress at investor events.
• Because the company has said it will not necessarily update the deck, investors should rely on formal filings (e.g., 10-Q/10-K, press releases) for confirmed financial or material changes and treat the presentation as supplementary investor outreach under Regulation FD.